Skip to main content
ScholarsBetaWeill Cornell Medicine

Highlights

  1. 1
    Cancer discovery · 2020
    SCStefano CiriglianoRSRicha SinghaniaRRRohan RamakrishnaDJDavid J Pisapia+1 more →HAHoward Alan Fine
    PMID: 32253265PMCID: PMC10256258DOISenior author143 citations
  2. 2
    Cancer research · 2023
    SCStefano CiriglianoRSRicha SinghaniaHAHoward Alan Fine
    PMID: 36877162PMCID: PMC11022245DOISenior author20 citations
  3. 3
    Acta neuropathologica communications · 2024
    SCStefano CiriglianoRSRicha SinghaniaBLBenjamin LiechtyHAHoward Alan Fine
    PMID: 38528608PMCID: PMC10964514DOISenior author19 citations

Publications

233 publications

Funding

15 grantsView NIH portfolio on RePORTER ↗

Active

5 grants
  • Co-I
    New York-New Jersey Center for Actionable NeuroHIV Biomarkers and Integrated Omics (NYJ-CAN-BIO)
    National Institute of Mental Health · 2026–2030
    P30MH144896-01
  • MPI
    Identifying and Targeting 3D Regulatory Nodes that Maintain Glioblastoma Programs
    National Institute of Neurological Disorders and Stroke · 2024–2029
    R01NS136475-03
  • Co-I
    Ultra-High Performance Brain-dedicated PET scanner for Neurology and Neuro-oncology imaging
    National Cancer Institute · 2023–2028
    R01CA275942-01A1
  • Co-I
    Elucidating single cell changes in neurogenic brain regions during HIV and cannabinoid exposure
    National Institute on Drug Abuse · 2023–2028
    U01DA058527-04
  • Co-I
    Development of Brain Organoids to Study the Impact of HIV-1, Drugs of Abuse and Aging on Cognitive Impairment
    National Institute on Drug Abuse · 2020–2026 · via The Feinstein Institute for Medical Research· 2 renewals
    R01DA052027-06
Completed grants (10)
  • KP
    Targeting cysteine susceptibility in glioblastoma
    National Institute of Neurological Disorders and Stroke · 2022–2024
    K08NS128263-01
  • PI
    State Selective Lethality: Exploiting a Previously Unrecognized Therapeutic Vulnerability in Glioblastoma
    William Rhodes Center for Glioblastoma - Collaborative Research Initiative · 2022–2023
    WRCG 223502-01
  • KP
    Weill Cornell Medicine (WCM) SPORE in Prostate Cancer
    National Cancer Institute · 2017–2023
    P50CA211024-05
  • PI
    Addgene 705296
    Addgene, Inc. · 2022–2023
    Addgene 705296
  • Co-I
    Deciphering cellular hierarchies and plasticity in diffuse gliomas by single-cell multi-omics
    New York Presbyterian Hospital · 2020–2022
    NYPH 203205-01
  • PI
    Human Brain Cancer, Rather Than Brain Cancer Cells, on a Plate
    National Cancer Institute · 2017–2022
    DP1CA228040-05
  • Co-I
    Discovery And Validation Of Novel Therapeutic Strategies In Glioblastoma
    New York Presbyterian Hospital · 2020–2022
    NYPH 205034-01
  • PI
    Dr. M.S. (Peg) AtKisson (consultant) of AtKisson Training Group, LLC (ATG) to provide an independent consultation for Nanus-Fine submission to NCI PAR-19-242
    AtKisson Training Group, LLC · 2019–2020Contract
    CA 193790-01
  • KP
    Exploring the Regulation and Function of Gap Junction-Mediated Signaling in Glioblastoma Multiforme
    National Cancer Institute · 2017–2019Fellowship
    F32CA217048-02
  • PI
    Determine the Activity of FT-7794 In-Bivo in Human Orthotopic GBM Patient-Derived Models (Exhibit B Supplement)
    Forma Therapeutics · 2017–2018Contract
    Forma RAA

Clinical research

6 studies
Completed & closed trials (6)
  • PI
    A Phase 2 Trial of Paxalisib Combined With a Ketogenic Diet and Metformin for Newly Diagnosed and Recurrent Glioblastoma
    PHASE2 · Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2025)
    Glioblastoma
    NCT05183204
  • PI
    A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Enzastaurin Added to Temozolomide During and Following Radiation Therapy in Newly Diagnosed Glioblastoma Patients Who Possess the Novel Genomic Biomarker DGM1
    PHASE3 · Denovo Biopharma · IRB STUDY CLOSURE (as of 2024)
    Glioblastoma
    NCT03776071
  • PI
    Compassionate Use of Vorasidenib for Treatment of Glioma in Patient S-M
    Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2024)
  • PI
    Compassionate Use of Vorasidenib for Treatment of IDH-Mutated Astrocytoma in Patient Y-F
    Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2024)
  • PI
    A Randomized, Multicenter, Adaptive Phase 3 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy (WIZARD 201G)
    PHASE3 · Boston Biomedical Inc. · IRB STUDY CLOSURE (as of 2022)
    Glioblastoma
    NCT03149003
  • PI
    A Phase II, Open Label, Single Arm Study of Nivolumab for Recurrent or Progressive IDH Mutant Gliomas With Prior Exposure to Alkylating Agents
    PHASE2 · Columbia University · IRB STUDY CLOSURE (as of 2021)
    Gliomas
    NCT03557359

Available technologies

1 technologyView full WCM portfolio ↗

News mentions

1 mentionView all WCM news ↗
  • Three-Dimensional Gene Hubs May Promote Brain Cancer
    April 21, 2025

    The way DNA folds inside the nucleus of brain cells may hold the key to understanding a devastating form of brain cancer called glioblastoma, suggests a new preclinical study from Weill Cornell Medicine researchers.

Mentoring

7 menteesAll publications with mentees →